IBD-Associated Arthritis News

Celltrion has submitted a biologics license application to the FDA for the consideration of a subcutaneous formulation of infliximab in the treatment of inflammatory bowel disease, according to a press release.

PHILADELPHIA — Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.

In patients with autoimmune rheumatic diseases, vaccination against COVID-19 does not appear to correlate with increased flares, regardless of disease status, previous exposure and vaccine type, according to data published in Rheumatology.

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.

The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon.

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.

ORLANDO — Altered gut flora has the potential to impact autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, noted a speaker at the 2022 Rheumatology Nurses Society Conference.

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.

Sometimes, the best way to care for a patient is to know one’s own limitations.

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.